Genomed Spólka Akcyjna Stock Price

Genomed Spólka Akcyjna provides DNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing of phage genetic material or bacteria genomes; and next-generation sequencing and genetic counseling services. In addition, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through e-store. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. The company was founded in 2007 and is based in Warsaw, Poland.